

# A study of early continuous positive airway pressure in acute respiratory failure in children with impaired immunity

<b>Submission date</b> 19/10/2012	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 14/11/2012	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 22/07/2020	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Mild breathing difficulties are common in children with weakened immunity. However, if a child develops severe breathing difficulties, this can result in damage to the lungs to the point where they no longer function properly and the child requires support from a special machine called a mechanical ventilator, which breathes for them. Currently, if a child develops severe breathing difficulties, they are treated on the ward with oxygen, antibiotics and careful control of fluids. If, despite this treatment, their breathing difficulties get worse, they will usually be admitted to the intensive care unit for further treatment. This often involves the child receiving a general anaesthetic to allow them to be attached to a mechanical ventilator to help them breathe. Recent studies in adults with impaired immunity have shown that it might be better to admit patients to the intensive care unit earlier, before their breathing problems get worse, for a treatment called continuous positive airway pressure (CPAP). CPAP is a technique for keeping lungs well inflated by the use of gentle air pressure via a face mask. In theory, holding the lungs open a little more with the extra pressure of CPAP should make the effort of breathing less, and reduce the risk of further chest infections. Patients in the studies who received CPAP early were less likely to need a general anaesthetic and mechanical ventilation. However, these studies only involved small numbers of patients who were all adults. More research is needed which also includes children. We do not know if early treatment with CPAP is better, so the purpose of this study is to find out if early admission to the intensive care unit for CPAP results in more children recovering from severe breathing difficulties compared to usual treatment.

### Who can participate?

Children aged less than 18 years who are being treated at participating hospitals, with weakened immunity and severe breathing difficulties.

### What does the study involve?

If a child is assigned to the CPAP group, he/she will be admitted to the intensive care unit and have CPAP delivered via a face mask for a minimum of 12 hours per day for at least four consecutive days. After this, the child will receive usual treatment as directed by the medical team which may or may not include continuing with CPAP. The child will be monitored closely by

the medical team. If a child is assigned to the usual treatment group, he/she will continue to receive treatment on the ward, including oxygen therapy, antibiotics and fluids. The child will be monitored closely by the medical team. If the child requires more intensive treatment, he/she will be admitted to the intensive care unit in accordance with standard acutely ill child protocols and as deemed necessary by the ICU outreach/medical rapid response teams and the clinical team responsible for the child's care.

What are the possible benefits and risks of participating?

Participants will be playing an important part in finding out what is the best way to help young people like them to get better. We can't promise this research will help children, but they will be helping others just like them who have the same problems in the future. All medical procedures, regardless of study participation, involve some risk of injury. We are doing this study because we do not know if early admission to the intensive care unit for CPAP is better than continuing treatment on the ward. Delivery of CPAP requires the child to wear a moderately tight-fitting face mask and it is possible that they may not feel comfortable with the face mask on. However, most children with severe breathing difficulties recognise very quickly that once the face mask is in position that breathing is much easier. If a child does find the face mask difficult to tolerate, the medical team will make a decision about whether to try gentle sedation to assist with the CPAP or to leave the face mask off. If the face mask is used for many days there is a risk of areas of skin becoming sore where the face mask is in contact with the skin, particularly on the bridge of the nose. This risk can usually be minimised by giving rest periods off the CPAP mask or by changing the mask shape from time to time.

Where is the study run from?

The study will take place at four NHS hospitals in the UK and is being managed by the Intensive Care National Audit & Research Centre (ICNARC).

When is the study starting and how long is it expected to run for?

The study will run from January 2013 to January 2016.

Who is funding the study?

The study is being funded by the Great Ormond Street Hospital Children's Charity, Registered Charity No 235825.

Who is the main contact?

Dr Mark Peters  
mark.peters@ucl.ac.uk

## Contact information

### Type(s)

Scientific

### Contact name

Dr Mark Peters

### Contact details

Reader in Paediatric Intensive Care and Hon Consultant Intensivist  
Critical Care Group Portex Unit  
Institute of Child Health (UCL)  
30 Guilford Street

London  
United Kingdom  
WC1N 1EH

## **Additional identifiers**

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
10AR31

## **Study information**

### **Scientific Title**

Randomised Study of early Continuous positive airway pressure in Acute Respiratory Failure in children with impaired immunity

### **Acronym**

SCARF

### **Study objectives**

Early admission to the paediatric intensive care unit (PICU) for delivery of continuous positive airway pressure (CPAP) will reduce the need for intubation and invasive mechanical ventilation within 30 days and improve survival from both acute and acute on chronic respiratory failure in children with impaired immunity.

On 07/07/2014 the following changes were made to the trial record:

1. The study design was changed from 'Single centre pragmatic open randomised controlled trial' to 'Multi-centre pragmatic open randomised controlled trial'
2. The anticipated start date was changed from 09/11/2012 to 01/01/2013
3. The anticipated end date was changed from 08/11/2016 to 01/01/2017

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

NRES Committee London - Riverside, 13/08/2012, ref: 12/LO/1051

### **Study design**

Multi-centre pragmatic open randomised controlled trial

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

**Study setting(s)**

Hospital

**Study type(s)**

Treatment

**Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

**Health condition(s) or problem(s) studied**

Acute respiratory failure in immune impaired children

**Interventions**

Current interventions as of 07/07/2014:

**Intervention group**

Participants allocated to the intervention group will be admitted to the PICU and receive Continuous Positive Airway Pressure (CPAP) of at least 6 cm of water (PEEP) with supplemental oxygen for a minimum of 12 hours per day for at least four consecutive days. The interface for delivering CPAP (i.e. via face mask, helmet or infant flow-driver) will be at the discretion of the clinical team responsible for the patients care. All other care will be determined by the clinical team primarily responsible for the patients care.

**Control group**

Participants allocated to the control group will remain on the ward and receive supplemental oxygen to maintain oxygen saturation in accordance with standard local practice. All other care (including antimicrobial therapy, fluid therapy, analgesia and sedative agents, bronchodilator therapy) will be determined by the clinical team primarily responsible for the child's care.

Participants in the control group will be admitted to the PICU in accordance with standard acutely ill child protocols and as deemed necessary by the ICU outreach/medical rapid response teams and the clinical team responsible for the child's care.

**Previous interventions:****Intervention group**

Participants allocated to the intervention group will be admitted to the PICU and receive Continuous Positive Airway Pressure (CPAP) of at least 6 cm H<sub>2</sub>O with supplemental oxygen for a minimum of 12 hours per day for at least four consecutive days. The interface for delivering CPAP (i.e. via face mask, helmet or infant flow-driver) will be at the discretion of the clinical team responsible for the patients care. All other care will be determined by the clinical team primarily responsible for the patients care.

**Control group**

Participants allocated to the control group will remain on the ward and receive supplemental oxygen to maintain oxygen saturation in accordance with standard local practice (Level 1 respiratory support see: Section 10.3). All other care (including antimicrobial therapy, fluid therapy, analgesia and sedative agents, bronchodilator therapy) will be determined by the clinical team primarily responsible for the child's care. Participants in the control group will be admitted to the PICU in accordance with standard Great Ormond Street Hospital acutely ill child protocols and as deemed necessary by the Intensive Care Outreach Network/Clinical Site Practitioner and the clinical team responsible for the child's care.

**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome measure**

Requirement for intubation and invasive mechanical ventilation within 30 days post-randomisation

**Secondary outcome measures**

1. Maximum and aggregate daily organ failure score
2. Mortality at 30 days post-randomisation
3. Requirement for Level 2 or Level 3 respiratory support within 30 days post-randomisation
4. Days free from any ventilator support at 30 days post-randomisation
5. Days free from supplemental oxygen (i.e., above pre-acute respiratory failure requirement) at 30 days post-randomisation
6. Hospital mortality
7. Mortality at 90 days post-randomisation
8. Mortality 1 year post-randomisation

**Overall study start date**

01/01/2013

**Completion date**

01/01/2017

**Eligibility****Key inclusion criteria**

Current inclusion criteria as of 07/07/2014:

1. Age less than 18 years
2. Expected to have impaired immunity for at least 3 months as a result of a primary diagnosis, therapy or a combination of both
3. Acute respiratory failure or acute on chronic respiratory failure

Previous inclusion criteria:

1. Age less than 16 years
2. Expected to have impaired immunity for at least 3 months as a result of a primary diagnosis, therapy or a combination of both
3. Acute respiratory failure or acute on chronic respiratory failure

**Participant type(s)**

Patient

**Age group**

Child

**Upper age limit**

18 Years

**Sex**

Both

**Target number of participants**

148

**Total final enrolment**

114

**Key exclusion criteria**

1. Already receiving invasive mechanical ventilation for non-respiratory indications
2. Other acute indication for emergency PICU admission and invasive mechanical ventilation, independent of the degree of respiratory failure (e.g., shock, reduced level of consciousness, seizures), as assessed by the PICU team
3. Recent oesophageal/gastric surgery
4. End-of-life care plan in place with limitation of resuscitation
5. Life expectancy less than 12 months
6. Already receiving treatment on PICU

**Date of first enrolment**

01/01/2013

**Date of final enrolment**

01/01/2017

**Locations****Countries of recruitment**

England

United Kingdom

**Study participating centre**

Reader in Paediatric Intensive Care and Hon Consultant Intensivist

London

United Kingdom

WC1N 1EH

**Sponsor information****Organisation**

Great Ormond Street Hospital for Children NHS Foundation Trust (UK)

**Sponsor details**

Joint Research and Development Office  
Division of Research and Innovation  
NHS Foundation Trust & The UCL Institute of Child Health  
2nd Floor, 30 Guilford Street  
London  
England  
United Kingdom  
WC1N 1EH

**Sponsor type**

Hospital/treatment centre

**Website**

<http://www.gosh.org/>

**ROR**

<https://ror.org/03zydm450>

## Funder(s)

**Funder type**

Charity

**Funder Name**

Great Ormond Street Hospital for Childrens Charity (UK), ref: 235825

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/10/2018	22/07/2020	Yes	No